The Latest Cardiac and Vascular News
The Biome Performance Manager™ simplifies and accelerates clinical and financial performance improvement across cardiovascular subspecialties. Clinicians, care teams, and hospital leadership leverage scarce resources to manage more initiatives, achieve goals faster, and sustain gains. SAN FRANCISCO–(BUSINESS WIRE)–Biome Analytics, the leader in clinical performance solutions, is pleased to announce the release […]
UChicago Alumnus Antonio Gracias’ Family Foundation Invests in Early-Stage Atherosclerosis Research at The Pritzker School of Molecular Engineering The Gracias Family Foundation has committed $3 million to new early-stage nanomedicine research led by the University of Chicago’s Pritzker School of Molecular Engineering aimed at reducing atherosclerosis, the inflammation of the […]
— If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel delivery systems building on Company’s dedication to meeting clinicians’ evolving needs — DUBLIN, Sept. 28, 2022 /PRNewswire/ — Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced the submission of a […]
REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS, Sept. 27, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the activation of three additional sites […]
CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® now cleared for manufacturing from this site PRINCETON, N.J., Sept. 27, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that it has received ISO 13485 […]
WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock […]
HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced the presentation […]
Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ — Artivion, Inc. ( NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if […]
ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria CARLSBAD, Calif., Sept. 23, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. ( Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) […]
SHANGHAI, Sept. 23, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study on the world’s largest and most influential American transcatheter cardiovascular therapy conference (TCT 2022). PADN is an innovative radiofrequency ablation technique in treating PH, […]
